ClinicalTrials.Veeva

Menu
S

South Texas Accelerated Research Therapeutics | START San Antonio

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
Nivolumab
pembrolizumab
Docetaxel
Budigalimab
PF-07220060
PF-05082566
Pemigatinib
Vinorelbine
Patupilone

Parent organization

This site is a part of South Texas Accelerated Research Therapeutics

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

71 of 209 total trials

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

Enrolling
Advanced Breast Cancer
Drug: Elacestrant
Drug: MEN2312

The purpose of this study is to evaluate the safety and tolerability of:* casdatifan when taken alone in participants with advanced solid tumor malig...

Enrolling
Solid Tumors
Clear Cell Renal Cell Carcinoma
Drug: Zimberelimab
Drug: casdatifan

This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.

Enrolling
Advanced Solid Tumors
Drug: RO7623066
Drug: Olaparib

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in...

Enrolling
Advanced Solid Tumor
Drug: GEN1286

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will...

Enrolling
Advanced Solid Tumors with KRAS G12C Mutations
Solid Tumor, Adult
Drug: FMC-376

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patie...

Enrolling
Triple Negative Breast Cancer (TNBC)
Urothelial Cancer
Drug: ADRX-0706

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or re...

Enrolling
Advanced MTAP-null Solid Tumors
Drug: Comparator AMG 193 Test Tablet
Drug: Docetaxel

The primary objectives of this study are to:* Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in...

Enrolling
Advanced Solid Tumors
Drug: AMG 355
Drug: Pembrolizumab

The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in part...

Enrolling
Advanced Solid Tumors
Drug: Capecitabine
Drug: Docetaxel

CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumor...

Enrolling
Advanced Solid Tumor
Drug: CLN-619
Drug: Pembrolizumab

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209...

Enrolling
Endometrial Cancer
Lymphoma, T-Cell
Drug: CPI-0209

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with tem...

Enrolling
Astrocytoma, Grade III
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Drug: Debio 0123
Drug: Temozolomide

The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumo...

Active, not recruiting
Ovarian Neoplasms
Adenoid Cystic Carcinoma
Drug: Pembrolizumab
Drug: Felmetatug Vedotin

The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma.The mai...

Enrolling
Open Label
Oral Drug Administration
Drug: FX-909

The purpose of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 (Part 1: dose e...

Enrolling
Advanced Prostate Cancer
Drug: JNJ-78278343
Drug: JNJ-87189401

Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic can...

Begins enrollment this month
Clear Cell Adenocarcinoma of Vulva
Endometrial Cancer
Biological: Lorigerlimab

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast c...

Active, not recruiting
Breast Cancer
Drug: Anastrozole, Exemestane, or Letrozole
Drug: Paclitaxel

This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, t...

Active, not recruiting
Breast Neoplasms
Drug: Trastuzumab
Drug: Pertuzumab

The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in part...

Active, not recruiting
Endometrial Cancer
Breast Cancer
Drug: Trastuzumab
Drug: Everolimus

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or...

Enrolling
Esophageal Cancer
Advanced Solid Tumor
Drug: LY4101174

Trial sponsors

AbbVie logo
Lilly logo
Pfizer logo
Incyte logo
Merck Sharp & Dohme (MSD) logo
Amgen logo
Daiichi Sankyo logo
Gilead Sciences logo
A
Bristol-Myers Squibb (BMS) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems